Neuromuscular Blocking Agents
13
2
4
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
38%
5 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (13)
Antagonism of Neostigmine in Continuous Infusion of Mivacurium
NMBA Reversal and Postoperative Urinary Retention
Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Propofol Anesthesia
Measuring of the Duration of Action of Different Doses of Rocuronium-induced Neuromuscular Block in Infants During Surgical Treatment of Craniosynostosis
Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia
Study of the Relationship Between Curarization and Pneumoperitoneum in Laparoscopic Surgery
Impact of Deep Versus Standard Muscle Relaxation on Intra-operative Safety
Neuromuscular Blocking Agents in Cardiac Surgery
Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade
Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
Management of Neuromuscular Blocking Agents and Their Antagonism
Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium
Effect of Nitrous Oxide on Cisatracurium Infusion Demands